2010/06/13

DALFUSINUM

Pharmacological properties: antidizuricheskoe tool. Selectively blocking postsynaptic α 1-adrenergic receptors located in the triangle of the bladder, urethra and prostate gland, prevents spasm of sphincters of the bladder, urethra and prostate gland, reduces vnutriuretralnoe pressure. It improves urodynamic parameters: lowering the tone of the urethra and the resistance of the outflow from the bladder facilitates the process of emptying, significantly increases the maximum rate of urine outflow, reduces residual urine volume, causing a strong urge to urinate due to increased volume of urine.

Well absorbed in the gastrointestinal tract. The maximum plasma concentration achieved after 3 h. The binding with plasma proteins is about 90%. The half alfuzozina - 8 pm Only 11% alfuzozina excreted unchanged in the urine. Metabolised in the liver, the majority of inactive metabolites (75-91%) is excreted in the feces.

Elderly patients noted a higher plasma concentration and bioavailability (possibly by reducing the metabolism in the liver), volume of distribution decreases, half-life remains unchanged. In patients with renal insufficiency volume of distribution increases, and the total clearance alfuzozina increases (perhaps by reducing the binding to plasma proteins). Even in the case of severe renal insufficiency not cumulative due to intense biotransformation. In chronic heart failure pharmacokinetic parameters are not changed.

INDICATIONS: Symptomatic treatment of benign prostatic hyperplasia.

APPLICATION: designate an adult male inside after eating without chewing 1 tablet (5 mg) morning and evening. Elderly patients and patients with renal failure and / or patients receiving antihypertensive therapy, prescribed 1 tablet in the evening, and if necessary increase the dose to 2 tablets (morning and evening).

The maximum daily dose - 2 tablets (10 mg).

CONTRAINDICATIONS: Hypersensitivity to any component of the drug, orthostatic hypotension, simultaneous reception of other α 1-blockers, hepatic failure.

SIDE EFFECTS:

From the CNS: headache, dizziness, tinnitus, weakness, seldom - syncope, asthenia, somnolence.

Since the cardiovascular system: rarely - orthostatic hypotension, palpitation, tachycardia, aggravation of symptoms of angina (in patients with coronary heart disease), pain in the chest, edema, flushing.

On the part of the digestive system: nausea, diarrhea, pain in the epigastric region, rarely - dry mouth.

Other: rarely - skin rash, itching.

Cautions: Patients with coronary heart disease, hypertension, renal failure receiving antihypertensive therapy, dosage adjustment is necessary. If during therapy the worsening angina pectoris, the drug should be abolished. The drug can be prescribed as in AH, and at a normal level of blood pressure, in the latter case, blood pressure reduction is not significant.

Because while taking the drug may develop hypotension and dizziness, is not recommended to drive vehicles or to perform work that requires increased attention.

Not intended for use in women and children.

INTERACTION: incompatible with other blockers, α 1-adrenoceptor. The drug potentiates the effects of antihypertensive agents and general anesthetics (possible instability BP).

OVERDOSE:

Symptoms: hypotension. The patient must be in the supine position.

Treatment: symptomatic - Introduction vasoconstrictor agent, p-ditch high molecular substances that increase the BCC. Hemodialysis is ineffective.

Storage: Store in dark place at a temperature of 25 ° C.